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An exploratory study of the role of trust 
in medication management within mental 
health services 
 
 
INTRODUCTION 
Trust is a fundamental aspect of human relations and becomes relevant in 
conditions of vulnerability and uncertainty1. Vulnerability is unavoidable in 
healthcare due to underlying anxiety associated with ill health, potential treatment 
risks, and the reliance of patients on clinicians2. Uncertainty exists in terms of 
treatment efficacy and adverse events3,4. Vulnerability and uncertainty are 
especially apparent in mental health contexts. While trust is vital to the co-
operation between service users and clinicians required in chronic disease 
management2 trust may be less likely in mental healthcare5.  
 
Taking medication is associated with vulnerability and uncertainty and therefore 
trust is likely to play a role in safe medication management4,6. However, trust may 
be difficult to obtain due to perceptions of coercion and because clinicians may 
believe that service users lack decisional capacity7-9. Adherence strongly 
correlates with trust and open communication about adverse effects facilitates 
such trust. Clinicians may be reluctant to provide information about adverse 
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effects due to fears that such an explanation could worsen adherence6,10. An 
over-emphasis on compliance and control, and a corresponding lack of open 
communication, may thus damage trust where patients experience negative 
outcomes they were not warned about. Incomplete and inaccurate exchange of 
information may compromise effectiveness and impair medication safety.7,11,12 
For example patients who are not warned about a particular adverse event - due 
to lack of trust regarding concordance - may not know how to manage it, or 
whether urgent treatment is needed. Moreover if a clinician does not have an 
accurate history, because the patient lacks trust in the clinician, it can be difficult 
to formulate safe treatment decisions.10,12  
 
AIM OF THE STUDY 
To develop understandings of the role of trust in safe medication management 
within mental health services. 
 
 
METHOD 
An exploratory qualitative approach following adopted COREQ (consolidated 
criteria for reporting qualitative studies) guidelines was used with approval by 
East Kent Research Ethics Committee (09/H1103/36)13. Focus groups were used 
because the group interaction allows participants to compare and contrast their 
views and experiences, enabling key issues to be developed from multiple 
participants14. With complex issues, such as the use of medication in mental 
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healthcare, it can be difficult to frame the questions and the group format allows 
participants to develop the questions and identify solutions.  
 
Sample 
Focus groups were run across three categories of user of specialist secondary 
care mental health services – older adult, adults living in the community, and 
forensic services (one focus group per service) – to develop understandings 
across varying settings. (In the UK specialist services tend to focus on people 
with complex mental healthcare requirements, such as, psychosis, whereas most 
care for uncomplicated care particularly depression and anxiety is provided solely 
within primary care).15,16 Groups were segmented to contain participants with 
certain common characteristics and data was systematically captured to identify 
commonalities and differences between groups. The number of groups was 
based upon the necessary number of participants to provide a broad range of 
perspectives across different mental health contexts.  
 
A mixture of purposive and convenience sampling was used. Sites were based 
on what was appropriate to obtain a range of different views (purposive 
sampling) and where groups were relatively easy to form (convenience 
sampling). Each group contained 6 to 8 participants (see table 1 for sample 
characteristics, mean age and standard deviation). Potential participants were 
contacted via mail, a poster and/or an informal approach from the focus group 
co-facilitator, who also obtained informed consent. The key inclusion criterion 
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was users, or carers (in the case of the older adult service), of secondary mental 
health services. Participants who lacked capacity to consent would have difficulty 
with focus groups and were excluded.  
 
 
Insert Table 1 here. 
 
Procedure 
Focus groups lasted 1 to 1.5 hours and were conducted between August 2009 
and January 2010. The groups took place on NHS premises and were co-
facilitated by a research assistant or service user representative who was familiar 
with the participants, but had no treatment role. A semi-structured interview 
schedule (see appendix) was developed to explore service users’ views on the 
nature and influence of trust on medication management.  
 
Data Analysis 
The chief investigator carried out a thematic analysis of the transcripts using the 
method of constant comparison informed by grounded theory. Three coding 
stages were followed17. First, open coding was used to develop categories and 
sub-categories based on commonly recurring themes. Second, axial coding was 
used to compare categories and develop concepts and theories. Third, selective 
coding was used to re-organise the data and consider the themes in relation to 
trust. A number of techniques were used to ensure validity and reliability, and 
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control for researcher effects and selectivity in data use. Data was independently 
reviewed by one of the investigators and considered in the light of existing 
literature. Results which contradicted the key conclusions were actively pursued 
(deviant case analysis). Finally, member-checking was utilised. 
 
Reflexivity 
Qualitative researchers engage very closely with the study participants and must 
recognise the impact of personal bias and reflexivity, the relationship between 
the researcher and the participants, on the research outputs13. This research, 
including moderating the focus groups, was carried out by a male pharmacist 
with over 15 years experience working within mental healthcare. The researcher 
had no clinical role with any of the participants. 
 
 
RESULTS  
Three main themes, described below, were identified -  
 
Therapeutic Relationship 
 
Quality therapeutic relationships – reflecting clear communication, choice and 
empathy – were vital in developing trust. Each group emphasised that full 
communication developed trust:  
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“They actually told me about most of the side-effects and what was happening. 
So for me I did really trust the doctors on what they said (Forensic [F]; 6).” 
 
Service users frequently reported incomplete disclosure of information. Generally 
it was felt that clinicians tended to emphasise the ‘good’ effects of medication, 
seemingly to encourage adherence and not fully communicate the ‘bad’ effects of 
medication. This failure to inform damaged trust and inhibited the involvement of 
service users in medication safety, increasing risk:  
 
“They should tell you more (about side-effects) and I think that when they are 
talking to you about medication they want you to take they should be prepared to 
tell you that these are the side-effects that you should look out for, because some 
of them may be dangerous (Older Adult [OA]; 9).” 
 
One view expressed across the three groups was a lack of choice particularly 
amidst compulsory treatment: 
“They tell us what medicines to take; we do not get a choice (F; 2).” 
 
A lack of choice was disempowering and could increase the risk associated with 
medication, and due to the reciprocal nature of trust, damaged service users’ 
trust and adherence – particularly if specific concerns were ignored18. Not all 
service users felt that there was a lack of choice. Articulate, well-informed service 
users were able to negotiate choice building trust: 
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“The staff have always listened to me about side-effects and when to change a 
medication, but that might not be true for everyone else (F; 4).” 
 
However, even in this sub-group choice was constrained and was typically 
reactive; medication would only be modified after an adverse event. Furthermore, 
every group believed that service users had a limited voice in relation to 
medication management, partly because clinicians believed that cognitive 
impairment prevented service users from identifying adverse events and that due 
to symptoms of their illness service users may falsely highlight a potential 
medication error to avoid receiving medication. Service users felt particularly 
unable to highlight an adverse event or query a prescription if acutely unwell and 
cognitively impaired, when high doses are used and medication commonly 
changed. Therefore, service users are most vulnerable to adverse events, and 
least able to report an adverse event, when one is most likely:  
 
“It’s general policy when you first go in for them to knock you out for more than a 
48 hour period, so if they start giving you wrong drugs you’re not going to be in 
much of a state to argue the toss? (Adult-Community [AC]; 18).” 
 
Experiencing an adverse event could damage trust in the medication, the 
clinician, and correspondingly adherence, particularly where the service user felt 
their views were ignored, the adverse event affected their quality of life, or the 
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medication had no noticeable benefit. However, adverse events did not always 
damage trust. One service user continued to trust the doctors despite medication 
induced thyroid problems:  
 
“I trust them to give me the right drugs. I have always trusted them (AC; 19).” 
 
Continuity of care was important and service users, particularly in the older adult 
and adult-community groups, were more likely to trust clinicians who were seen 
to take time in developing a relationship and demonstrate empathy. There was 
seemingly a reciprocal relationship between communication and trust, with the 
potential for improved outcomes within trusting relationships:   
 
“I think it goes back to treating people holistically and as individuals……. You 
have to build up a rapport with them on both sides in order that you both develop 
trust with each other. It helps you get better, because you trust somebody you 
know they are doing it in your best interests (OA; 9).” 
 
Uncertainty and Vulnerability 
 
Service users believed that the use of medication within mental healthcare was 
characterised by inherent uncertainty and guesswork: 
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“The most interesting thing is this arbitrary nature which they go about doing 
these things. Working out what medication you need, how long, how much of it 
you have to be on (F; 3).” 
 
This uncertainty was a barrier to trust, while also making trust necessary. There 
was initial uncertainty regarding the presence of disease with clinicians and 
service users holding different belief systems regarding mental illness8. Further 
uncertainty was associated with efficacy, side-effects and the role of medication 
in recovery, resulting in service users questioning the competence of clinicians.  
Several service users suggested clinicians overcame uncertainty by “objectifying” 
service users, and failing to individualise treatment, which damaged trust:  
 
“They make their mind up as to which drug you are going to go on. And their 
reasoning well I mean it could be ‘we fancy you on that drug’ and that’s it and I 
don’t trust them in that way (F; 2).” 
 
Where efficacy was uncertain, service users were reluctant to adhere to 
treatment – and if the clinician did not listen to the service user’s concerns this 
damaged trust: 
 
“It is of no consequence……my mood never changes…..Well, I suggested that 
she take me off drugs – I didn’t think that they were having enough effect. She 
said no – she dismissed it completely, instantly. (F; 5).” 
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Medication could have a significant effect. Service users could re-lapse if the 
dose was reduced, but were also vulnerable to adverse effects, which could 
damage trust and, due to incomplete disclosure, be unexpected and particularly 
frightening:  
 
“They put me on some medication I didn’t know what it was, but I thought that I 
was dying…..I couldn’t move (F; 6).” 
 
Vulnerability was inherent within the illness experience and some service users 
believed that, to a certain extent, they had to trust the doctors. Cognition could be 
impaired, by mental illness and medication, making it very difficult for service 
users to express a view19. Even when service users did express their viewpoint, 
they felt that due to the stigma of mental illness clinicians would often not listen: 
 
“And when you question it they just say ‘we think that you are mentally ill’. (F; 2).” 
 
The terminology used, the symptoms of mental illness (in particular paranoia), 
and observing outcomes in others re-enforced vulnerability – often creating a 
barrier to developing a trusting relationship. 
 
Service users identified that if they were educated about medication this could 
protect against vulnerability: 
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“I think to be educated on some of the things, you can build up much more of an 
idea of whether what is going on is right (OA; 8).” 
 
However, cognitively impaired and/or isolated service users may not be able to 
access accurate information. GPs were particularly vital in providing information, 
but unfortunately appropriate support was not always forthcoming: 
 
“My GP..… he doesn’t get involved. He won’t make any decision (AC; 20).” 
 
Generally, service users, particularly in the forensic group, did not trust statutory 
safeguards, and did not believe that service users under a section were 
adequately protected from receiving inappropriate medication: 
 
“I think that if I had refused it would have gone to the second opinion doctor and 
according to what other people have said then they would have just agreed with 
the first opinion doctor (F; 4).” 
 
However, in some cases safeguards were considered more robust.  
 
Social Control 
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Trust relates to beliefs that one’s concerns and interests will be prioritised by the 
trustee5. Yet service users believed that coercion was not for their well-being or 
in their best interests, but a symptom of an over emphasis on medication and 
concerns about the risks posed by service users – which are similarly uncertain. 
Coercion was frightening and traumatic, destroyed trust, and made service users 
feel vulnerable:  
 
“And force doesn’t promote trust, it promotes fear (AC; 16).” 
 
After coercion the therapeutic relationship was described as becoming more 
confrontational, with an increased need for future coercive treatment. Service 
users believed that they had no voice, or rights, under coercive treatment and it 
was unclear to them whether there were adequate safeguards to prevent 
medication errors: 
 
“Because some of the times I didn’t need it. They would just think that you did, 
but sometimes they would get the wrong decision (F; 6).” 
 
The use of coercion was related to fears about adherence and a lack of trust. 
Non-adherence was not tolerated and service users were often not trusted to 
adhere to medication, or to be honest about adherence. Clinicians did not always 
disclose this lack of trust. Service users were however aware of certain signs – 
such as use of depots – that indicated a lack of trust and damaged the 
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therapeutic relationship. If service users asserted what they believed was their 
right to refuse medication, coercive methods were used as a threat to enforce 
compliance in an already vulnerable population: 
 
“I wasn’t comfortable with the tablets so I tried it [refusing medication] and I was 
forced in my view (F; 6).” 
 
 
DISCUSSION  
 
The Role of Trust   
Every group identified the need to trust clinicians in relation to medication 
management20. However, achieving trust was often problematic; service users 
described the difficulty in developing a therapeutic relationship based on mutual 
trust21. Clinicians were typically seen as only trusting service users who agreed 
with them, exhibiting less trust if the service user opposed their views, which 
resulted in a failure to communicate fully. Service users didn’t, therefore, trust 
clinicians to tell them the whole truth about medication, particularly adverse 
events5. Respondents perceived this lack of trust by clinicians as disempowering, 
because it limited choice in relation to medication and resulted in the use of 
coercion22,23. The use of coercion destroyed any trust that the service user 
placed in the clinician, because service users believed that coercion was not for 
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their benefit, but an instrument of social control, and that safeguards failed to 
provide adequate protection.  
 
Inherent uncertainty exists around the use of mental health medication, which 
makes trust more necessary and yet unlikely5. This uncertainty is accompanied 
by vulnerability, partly because service users are often isolated, cognitively 
impaired and therefore not able to, or allowed to, make informed choices. 
Individual vulnerability and uncertainty may be reinforced by treatment contexts – 
poor communication and unclear lines of responsibility – which further threaten 
patient safety19 and inhibit a trusting relationship from developing.  
 
Low levels of trust impacted upon medication management in two main ways. 
First, the lack of trust could damage adherence, and result in coercion and 
forcible administration. Adherence strongly correlates with trust; adherence rates 
may be 3 times higher where there are very high levels of trust.9,24 Service users 
were more likely to adhere, when complete information is supplied25, and to 
regimens that have been negotiated and reactance theory suggests that using a 
threat is likely to have a contrary effect and increase non-adherence26,27. 
Therefore, ultimately coercion may worsen adherence by inhibiting a trusting 
relationship from developing.  
 
Second, it could increase the potential for adverse events. A partnership, 
involving full and complete communication and informed choice, rooted in mutual 
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trust, is required to safely manage medication. However, within mental 
healthcare there is a tension between the need for social control and limiting the 
adverse effects of medication23. Service users believed that clinicians generally 
did not trust their views and opinions, inhibiting information exchange, and a 
therapeutic partnership from developing. This low level of trust could be 
considered a latent factor in Reason’s model of error causation and increase the 
risk of medication errors28. 
 
Practice and Policy Implications  
The increased potential for error places additional responsibility on practitioners, 
who must avoid dismissing medication safety concerns due to stigma. The 
current policy focus in England and Wales is risk reduction with an emphasis on 
the use of coercion5,11. This study indicates that utilising coercive methods, rather 
than emphasising a partnership built upon trust, could increase the risk 
associated with medication in terms of adverse events and the possible 
consequences of non-adherence. Safe medication management and improved 
adherence may be most effectively achieved by policies and practices which 
adopt a partnership, rather than a coercive, approach and focus on trust rather 
than risk. A good example of a strategy, which adopted a partnership approach, 
involved the use of advance directives in people with severe mental illness.18 
Adherence at 12 months was higher amongst service users, who were 
prescribed at least one medication requested in an advance directive (odds ratio 
= 7.8, 95% confidence interval 1.8 to 34.0).18 Therefore, orienting services 
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around trust may reduce risk by creating virtuous rather than vicious circles of 
compliance5.  
 
Strengths and weaknesses of the study  
The views reflect the experiences of service users in a single NHS trust. 
However, the trust is one of the largest in the country serving a very mixed 
population and likely to be broadly representative, although this issue should be 
explored across other populations, including black and minority ethnic 
populations. Furthermore, the rich data generated from the focus groups 
conducted in three very different environments resulted in relative data 
“saturation” and similar issues were identified within a broader study of patient 
safety29.   
One possible limitation is the group heterogeneity and therefore analysing the 
results from the groups together may be problematic. However, the data from 
each group was initially analysed separately and the participants generally 
expressed similar views in relation to a number of the core themes. There were, 
however, some important differences in the data generated by the three groups. 
Participants in the forensic group highlighted a general lack of trust in 
safeguards, whereas empathy and continuity of care were particularly important 
to participants in the older adult and adult focus groups.  
 
Future Research 
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These findings require confirmation and expansion. Trust needs to be studied in 
various contexts and data sources should be triangulated by interviewing 
clinicians to understand the clinician’s perspective on trust. Longer-term research 
objectives should include developing a reliable and validated scale to assess the 
overall level of trust in relation to medication management within mental health 
services and interventions to improve trust.  
 
CONCLUSION 
To summarise, trust is needed within mental healthcare to ensure safe 
medication management, but achieving the required level of trust is far from 
straightforward. The focus groups more commonly referred to vicious circles 
where low levels of trust, due to (and resulting in) poor communication, made 
adverse events and/or coercion more likely – further undermining trust. This 
contrasted to the virtuous circles apparent within trust-based scenarios where 
service users felt they were given more responsibility and tended to be more 
honest with clinicians, building further trust and improving adherence. 
Therefore, the current policy framework should focus on trust rather than risk in 
order to reduce risks associated with medication. Further research is required to 
confirm and expand these initial findings. 
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Appendix 
 
Focus Group Semi-Structured Interview Guide 
 
 Do you feel able to talk openly to your clinicians and tell them accurate and 
complete information about your medication?  
 
 Are you told the important potential adverse events? 
 
 When the adverse events of medication are discussed are your views listened 
to within the consultation?  
 
 Do you think that your clinicians give you a balanced picture about the risks, 
including adverse events, and benefits of treatment?  
 
 Have you ever received medication against your will? If yes, what impact did 
this have on your relationship with clinicians?  
 
 Have you ever come across a medication error in mental health?  
 
 How important do you think trust is in ensuring the safe use of medication?  
 
 Do you trust your clinicians to tell you the truth about medication? 
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 Does trust, in relation to the use of medicines, exist in mental health? 
 
 What does it mean for you to trust your doctor about medication?  
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Table 1 – Characteristics of focus group participants 
 
 Forensic group Older adult group Adults living in the 
community group 
Total number of 
participants 
6 8 6 
Number of females 0 (all male unit) 4 3 
Number of carers Not applicable 2 Not applicable 
Mean age1 (years) 40.3 (s.d.=17.87) 71.2 (s.d.=4.88)2 
54 (s.d.=7.07)3 
41 (s.d.=9.90) 
Ethnicity White British 
(n=6)  
White British (n=8) White British (n=6)
 
1 = mean age and standard deviation calculated using SPSS statistical package 
17.0. 
 
2 = Mean age of service users in older adult group 
 
3 = Mean age of carers in older adult group 
 
s.d. = Standard deviation 
 
 
